VIVAX Pharmaceuticals, s.r.o.
Basic details
- Company ID (IČO)
- 36006521
- Tax ID (DIČ)
- 2020440840
- VAT ID (IČ DPH)
- SK2020440840
- VAT
- Registered for VAT under §4 since 1/8/1996
- Registered office
- Moyzesova 868/67, 01701 Považská Bystrica
- District
- Považská Bystrica (SK0226)
- Legal form
- Spoločnosť s ručením obmedzeným
- Register entry
- Obchodný register Okresného súdu Trenčín, oddiel Sro, vložka 3427/R
- Main activity (SK NACE)
- 70.20 · Poradenské služby v oblasti podnikania a riadenia
- Employees
- 10-19 zamestnancov
- Established
- 17/7/1996
Commercial register
Data updated: 25/10/2026, 11:51 (26 days ago)
- Registered capital
- €9,965 (paid up €9,965)
- Acting for the company
- Spoločnosť zastupujú a za ňu podpisujú konatelia, každý samostatne.
Shareholders
- MUDr. Bronislav Čikofrom 10/12/2025
- MUDr. Martin Michelčíkfrom 10/12/2025
- MUDr. Róbert Naništafrom 10/12/2025
Statutory body
- MUDr. Bronislav Čikofrom 17/7/1996
This is a copy from the Register of Legal Entities, not a court extract for legal acts. Look up on orsr.sk
Peppol
Peppol ID 0245:2020440840
In the directory since 29/10/2026
Documents it receives
- Invoice
Technical identifier
urn:oasis:names:specification:ubl:schema:xsd:Invoice-2::Invoice##urn:cen.eu:en16931:2017#compliant#urn:fdc:peppol.eu:2017:poacc:billing:3.0::2.1 - Credit note
Technical identifier
urn:oasis:names:specification:ubl:schema:xsd:CreditNote-2::CreditNote##urn:cen.eu:en16931:2017#compliant#urn:fdc:peppol.eu:2017:poacc:billing:3.0::2.1
Access point
The access point could not be determined just now.
Bank accounts

SK21 1111 0000 0066 1640 9020
SK43 1111 0000 0066 1640 9012
SK65 1111 0000 0066 1640 9004
Accounts the Slovak Financial Administration publishes for VAT payers.
Connections
VIVAX Pharmaceuticals, s.r.o.
FinPOST.sk
Financial data
No selected figures are published for this company or year.
FinPOST.sk
Financial data
From the financial statements in the Register of Financial Statements (RÚZ), in euros, for the last 5 years (each column is one fiscal year). Not verified; shown as the company filed them.
In 2021, VIVAX Pharmaceuticals, s.r.o. increased its revenue by 15% to €10,261,617 and its profit rose by 330% to €840,860. Equity rose by 46% to €2,340,847 and the debt ratio fell to 76.94%.
In 2022, VIVAX Pharmaceuticals, s.r.o. decreased its revenue by 3% to €9,930,349 and its profit fell by 77% to €196,247. Equity rose by 4% to €2,435,606 and the debt ratio fell to 76.09%.
In 2023, VIVAX Pharmaceuticals, s.r.o. decreased its revenue by 17% to €8,235,476 and its profit fell by 98% to €4,332. Equity fell by 20% to €1,955,574 and the debt ratio rose to 77.25%.
In 2024, VIVAX Pharmaceuticals, s.r.o. decreased its revenue by 3% to €7,950,851 and made a loss of €277,153. Equity fell by 14% to €1,678,421 and the debt ratio rose to 81.01%.
In 2025, VIVAX Pharmaceuticals, s.r.o. decreased its revenue by 14% to €6,807,640 and its profit was €88,327. Equity rose by 4% to €1,748,236 and the debt ratio fell to 76.92%.
Revenue
VIVAX Pharmaceuticals, s.r.o.
| Year | Revenue |
|---|---|
| 2021 | €10,261,617 |
| 2022 | €9,930,349 |
| 2023 | €8,235,476 |
| 2024 | €7,950,851 |
| 2025 | €6,807,640 |
Profit
VIVAX Pharmaceuticals, s.r.o.
| Year | Profit |
|---|---|
| 2021 | €840,860 |
| 2022 | €196,247 |
| 2023 | €4,332 |
| 2024 | −€277,153 |
| 2025 | €88,327 |
- Revenue
- €10,261,617
- Profit
- €840,860
- Assets
- €10,149,830
- Equity and liabilities
- €10,149,830
- Equity
- €2,340,847
- Debt ratio What it shows: How much of its assets the company finances with borrowed funds.
How it is computed: (Liabilities + Accruals) / Assets - 76.94%
- Gross margin What it shows: The share of revenue left after the cost of goods, materials, energy and services.
How it is computed: Value added / Revenue - 14.10%
Financial statements as PDF
- Správa audítora.PDF 1.8 MB
- Príloha k účtovnej závierke POD.PDF 83 kB
- POD_2020440840_IR_2021_3294467_4474991.pdf 442 kB
The files open in the Register of Financial Statements (RÚZ) in a new tab.
- Revenue
- €9,930,349
- Profit
- €196,247
- Assets
- €10,186,541
- Equity and liabilities
- €10,186,541
- Equity
- €2,435,606
- Debt ratio What it shows: How much of its assets the company finances with borrowed funds.
How it is computed: (Liabilities + Accruals) / Assets - 76.09%
- Gross margin What it shows: The share of revenue left after the cost of goods, materials, energy and services.
How it is computed: Value added / Revenue - 5.25%
Financial statements as PDF
- Správa audítora.PDF 1.6 MB
- Príloha k účtovnej závierke POD.PDF 84 kB
- POD_2020440840_IR_2022_3624667_4865826.pdf 441 kB
The files open in the Register of Financial Statements (RÚZ) in a new tab.
- Revenue
- €8,235,476
- Profit
- €4,332
- Assets
- €8,596,905
- Equity and liabilities
- €8,596,905
- Equity
- €1,955,574
- Debt ratio What it shows: How much of its assets the company finances with borrowed funds.
How it is computed: (Liabilities + Accruals) / Assets - 77.25%
- Gross margin What it shows: The share of revenue left after the cost of goods, materials, energy and services.
How it is computed: Value added / Revenue - 1.93%
Financial statements as PDF
- Správa audítora.PDF 4.9 MB
- Príloha k účtovnej závierke POD.PDF 142 kB
- POD_2020440840_IR_2023_4045980_5335939.pdf 441 kB
- POD_OS_2020440840_IR_2023_4045980_6139483.pdf 132 kB
The files open in the Register of Financial Statements (RÚZ) in a new tab.
- Revenue
- €7,950,851
- Profit
- −€277,153
- Assets
- €8,837,817
- Equity and liabilities
- €8,837,817
- Equity
- €1,678,421
- Debt ratio What it shows: How much of its assets the company finances with borrowed funds.
How it is computed: (Liabilities + Accruals) / Assets - 81.01%
- Gross margin What it shows: The share of revenue left after the cost of goods, materials, energy and services.
How it is computed: Value added / Revenue - −0.26%
Financial statements as PDF
- Účtovná závierka PODindiv..PDF 138 kB
- POD_2020440840_IR_2024_4433847_5792662.pdf 441 kB
- POD_OS_2020440840_IR_2024_4433847_6139488.pdf 132 kB
The files open in the Register of Financial Statements (RÚZ) in a new tab.
- Revenue
- €6,807,640
- Profit
- €88,327
- Assets
- €7,573,611
- Equity and liabilities
- €7,573,611
- Equity
- €1,748,236
- Debt ratio What it shows: How much of its assets the company finances with borrowed funds.
How it is computed: (Liabilities + Accruals) / Assets - 76.92%
- Gross margin What it shows: The share of revenue left after the cost of goods, materials, energy and services.
How it is computed: Value added / Revenue - 6.55%
Financial statements as PDF
The files open in the Register of Financial Statements (RÚZ) in a new tab.
Assets
VIVAX Pharmaceuticals, s.r.o.
As of 31/12/2021
- €10,149,830 · 100.00%
As of 31/12/2022
- €10,186,541 · 100.00%
As of 31/12/2023
- €8,596,905 · 100.00%
As of 31/12/2024
- €8,837,817 · 100.00%
As of 31/12/2025
- €7,573,611 · 100.00%
Equity and liabilities
VIVAX Pharmaceuticals, s.r.o.
As of 31/12/2021
- €10,149,830 · 100.00%
As of 31/12/2022
- €10,186,541 · 100.00%
As of 31/12/2023
- €8,596,905 · 100.00%
As of 31/12/2024
- €8,837,817 · 100.00%
As of 31/12/2025
- €7,573,611 · 100.00%
Total income
VIVAX Pharmaceuticals, s.r.o.
| Year | Sales of goods, products and services | Sales of fixed assets and material | Other operating income | Interest income | Other financial income | Total |
|---|---|---|---|---|---|---|
| 2021 | €10,261,617 | €25,163 | €11,761 | €256 | €34,667 | €10,333,464 |
| 2022 | €9,930,349 | €7,767 | €5,309 | €5,375 | €27,520 | €9,976,320 |
| 2023 | €8,235,476 | €0 | €10,187 | €95,569 | €25,016 | €8,366,248 |
| 2024 | €7,950,851 | €23,890 | €17,158 | €10,649 | €42,718 | €8,045,266 |
| 2025 | €6,807,640 | €10,486 | €9,434 | €6,704 | €5,223 | €6,839,487 |
Costs
VIVAX Pharmaceuticals, s.r.o.
| Year | Cost of goods sold | Materials and energy | Services | Personnel costs | Depreciation | Other operating costs | Financial costs | Income tax | Total |
|---|---|---|---|---|---|---|---|---|---|
| 2021 | €7,952,191 | €40,292 | €822,700 | €136,768 | €38,411 | €176,674 | €32,601 | €292,967 | €9,492,604 |
| 2022 | €8,512,703 | €44,840 | €851,940 | €210,183 | €43,061 | €31,966 | €32,707 | €52,673 | €9,780,073 |
| 2023 | €7,200,933 | €40,196 | €835,812 | €190,498 | €39,832 | €21,883 | €20,028 | €12,734 | €8,361,916 |
| 2024 | €7,092,954 | €44,790 | €833,514 | €214,391 | €69,908 | €54,685 | €6,876 | €5,301 | €8,322,419 |
| 2025 | €5,393,052 | €52,857 | €915,630 | €225,734 | €83,724 | €35,860 | €32,228 | €12,075 | €6,751,160 |
Margins
VIVAX Pharmaceuticals, s.r.o.
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2021 | 14.10% | 11.03% | 8.19% |
| 2022 | 5.25% | 2.50% | 1.98% |
| 2023 | 1.93% | −1.01% | 0.05% |
| 2024 | −0.26% | −4.00% | −3.49% |
| 2025 | 6.55% | 1.77% | 1.30% |
Year-on-year change
VIVAX Pharmaceuticals, s.r.o.
| Year | Revenue | Profit |
|---|---|---|
| 2021 | 15% | 330% |
| 2022 | −3% | −77% |
| 2023 | −17% | −98% |
| 2024 | −4% | −6,498% |
| 2025 | −14% | – |
Financing structure
VIVAX Pharmaceuticals, s.r.o.
| Year | Equity | Provisions | Loans and assistance | Long-term liabilities | Short-term liabilities |
|---|---|---|---|---|---|
| 2021 | €2,340,847 | €0 | €3 | €1,013,586 | €6,795,394 |
| 2022 | €2,435,606 | €11,747 | €54 | €1,014,067 | €6,725,067 |
| 2023 | €1,955,574 | €19,169 | €0 | €1,014,394 | €5,607,768 |
| 2024 | €1,678,421 | €14,302 | €0 | €1,015,051 | €6,130,043 |
| 2025 | €1,748,236 | €14,274 | €23 | €1,092,821 | €4,718,257 |
Income tax
VIVAX Pharmaceuticals, s.r.o.
| Year | Income tax | Current tax |
|---|---|---|
| 2021 | €292,967 | €292,967 |
| 2022 | €52,673 | €52,673 |
| 2023 | €12,734 | €12,734 |
| 2024 | €5,301 | €5,301 |
| 2025 | €12,075 | €12,075 |
Data sources
- Financial Administration of the Slovak Republic · updated 20/11/2026
- Register of Legal Entities (Statistical Office of the Slovak Republic, licence CC BY 4.0) · updated 20/11/2026
- OpenPeppol Directory · updated 20/11/2026
- Register of Financial Statements (RÚZ) · updated 20/11/2026
We take the data from the public registers as they publish it, unchanged and untranslated. FinPOST is an information website and does not verify the data. This page may be up to 7 days old. How we handle the data (privacy policy, section 3.9)